Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis
Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after treatment cessation in Week 16-responder patients w...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Taylor & Francis Group
2026-12-01
|
| Цуврал: | Journal of Dermatological Treatment |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.tandfonline.com/doi/10.1080/09546634.2026.2636417 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|